Showdown: Vegetarier vs Fleischesser – ZDF

Amüsante Sendung mit überraschenden Ergebnissen:

Ist fleischlos leben wirklich gesünder und besser für die Umwelt? ZDFzeit macht den Test: Vier leidenschaftliche Fleischesser und vier überzeugte Vegetarier müssen gegeneinander antreten.

vvf2

Drug-antibody pair has promising activity in non-Hodgkin lymphoma

A toxin linked to a targeted monoclonal antibody has shown “compelling” antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.

The ongoing open-label phase 2 study presented at the American Society of Hematology (ASH) meeting was designed to test the activity of
brentuximab vedotin (Adcetris) in relapsed or refractory non-Hodgkin lymphoma (NHL) including B-cell cancers such as diffuse large B cell lymphoma (DLBCL).

discovery_medicine_beck_no53_figure_2c

The antibody-toxin compound has been approved for treatment of relapsed or refractory Hodgkin lymphoma and anaplastic T cell lymphoma, and its success prompted the trial in NHL, said Eric Jacobsen, MD, of Dana-Farber, senior author of the study. First author is Nancy Bartlett, MD, of Washington University School of Medicine.
To date, the trial has enrolled 62 patients with B-cell lymphomas, including 44 diagnosed with DLBCL. Most the patients were no longer responding to previous therapy, and 23 percent had never responded to any treatment.

Forty percent of the 43 evaluable DLBCL patients had an objective response to the drug with a median duration of 36 weeks, including some of more than eight months. Seven had complete remissions and 10 had partial remissions. In the other B-cell lymphoma patients, 22 had an objective response. Continue reading

Killing cancer like the common cold

Nick Wilkins was diagnosed with leukemia when he was 4 years old, and when the cancer kept bouncing back, impervious to all the different treatments the doctors tried, his father sat him down for a talk.

Cure of Leukaemia

John Wilkins explained to Nick, who was by then 14, that doctors had tried chemotherapy, radiation, even a bone marrow transplant from his sister.

“I explained to him that we’re running out of options,” Wilkins remembers telling his son.

There was one possible treatment they could try: an experimental therapy at the University of Pennsylvania.

He asked his son if he understood what it would mean if this treatment didn’t work.

Read More Here on CNN.com

Scientists Invent Oxygen Particle That If Injected, Allows You To Live Without Breathing


New Medical Discovery
A team of scientists at the Boston Children’s Hospital have invented what is being considered one the greatest medical breakthroughs in recent years. They have designed a microparticle that can be injected into a person’s bloodstream that can quickly oxygenate their blood. This will even work if the ability to breathe has been restricted, or even cut off entirely.

This finding has the potential to save millions of lives every year. The microparticles can keep an object alive for up to 30 min after respiratory failure. This is accomplished through an injection into the patients’ veins. Once injected, the microparticles can oxygenate the blood to near normal levels. This has countless potential uses as it allows life to continue when oxygen is needed but unavailable. For medical personnel, this is just enough time to avoid risking a heart attack or permanent brain injury when oxygen is restricted or cut off to patients.
Continue reading